Order — ECLI:EU:T:2018:730
Date: 2018-10-25
Language of the case: English
Court formation: President of the Chamber
Subject matter: Public health
Procedure: Action for annulment;Application for interim measures - inadmissible
Origin: Austria;France

Action brought on 1st of June 2018 – Laboratoire Pareva and Biotech3D v Commission (Case T-347/18) Language of the case: English Parties Applicants: Laboratoire Pareva (Saint Martin de Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers) Defendant: European Commission Form of order sought declare the application admissible and well-founded ; annul the European Commission’s Implementing Regulation (EU) 2018/6131 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 under Regulation 528/20122 (the "Contested Act") ; and order the defendant to pay the costs of these proceedings. Pleas in law and main arguments In support of the action, the applicants rely on three pleas in law which are in essence identical or similar to those relied on in Case T-337/18, Laboratoire Pareva v Commission. ____________ 1 Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018, L 102, p.1) 2 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012, L 167, p. 1)